Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event
January 05, 2023 07:00 ET
|
Ryvu Therapeutics
KRAKOW, Poland, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million
December 22, 2022 12:04 ET
|
Ryvu Therapeutics
KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
December 11, 2022 10:30 ET
|
Ryvu Therapeutics
RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet responses in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or...
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 23, 2022 12:15 ET
|
Ryvu Therapeutics
Updated Phase Ib data on RVU120 in relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndrome (HR-MDS) to be presented at the 2022 American Society of Hematology (ASH)...
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
November 03, 2022 09:30 ET
|
Ryvu Therapeutics
Six Presentations Highlight the Clinical and Preclinical Activity of RVU120 and SEL24 (MEN1703) RVU120 Demonstrates Single-Agent Activity with a Complete Response and Disease Stabilization in 10...
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
October 26, 2022 04:15 ET
|
Ryvu Therapeutics
Updated data from Phase I/II dose-escalation study of RVU120 show four disease stabilizations in advanced solid tumor patients,RVU120 was well tolerated across all doses evaluated,Preclinical data...
Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
October 12, 2022 03:15 ET
|
Ryvu Therapeutics
KRAKOW, Poland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
EIB to Support Ryvu Therapeutics’ Discovery, Research and Development of New Cancer Treatments with €22 Million
August 17, 2022 02:10 ET
|
Ryvu Therapeutics
Ryvu Therapeutics, an innovative biotech company, receives EIB financing to accelerate the development of new therapies to treat severe blood cancers and solid tumours, including further clinical...
Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board
July 26, 2022 03:30 ET
|
Ryvu Therapeutics
KRAKOW, Poland, July 26, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...